How Paloma Is Rebuilding Thyroid Care From the Ground Up

The Lab Says You're Fine. You're Not Fine.

There are roughly 20 million Americans living with some form of thyroid disease. Hypothyroidism, Hashimoto's thyroiditis, hyperthyroidism, Graves' disease — the thyroid gland, a butterfly-shaped organ smaller than your fist, is quietly responsible for regulating nearly every metabolic process in the human body. When it misfires, patients know. The fatigue is crushing. The brain fog is real. The weight gain happens despite every reasonable effort. The hair falls out in the shower. The cold sensitivity turns winter into a medical event.

And yet, for most of those 20 million people, the experience with the healthcare system follows a brutally predictable script: a single TSH test, a levothyroxine prescription, a follow-up in three months, and a reassurance — delivered in the seven minutes a primary care physician can spare — that everything looks normal. That's it. That's the standard of care for one of the most common chronic conditions on the planet.

The mismatch between what patients experience and what the medical system acknowledges has created a quiet crisis. Patients cycle through symptoms, adjust their own dosages in desperation, fall down research rabbit holes trying to understand what Free T3 even means, and eventually start wondering if what they're feeling is all in their head. It isn't. The problem is in the protocol.

Paloma was built to fix the protocol.

What Paloma Does: Complete Thyroid Care, Finally

Paloma is a virtual thyroid care platform that replaces the fragmented, inadequate standard of care with something actually designed around thyroid physiology. The platform integrates three things that have never existed together in one place: comprehensive at-home lab testing, specialist telehealth with endocrinologists who actually focus on thyroid conditions, and longitudinal symptom tracking that connects the dots between how a patient feels and what their labs show.

It starts with the test. Paloma's at-home blood test doesn't just measure TSH — it measures the complete thyroid panel: TSH, Free T3, Free T4, TPO antibodies, and Reverse T3. These are the markers that tell the full story. A patient can have a technically normal TSH while their Free T3 — the active hormone that cells actually use — is in the tank. A patient with elevated TPO antibodies has an autoimmune condition (Hashimoto's) that changes the entire treatment calculus. None of this shows up on a standard TSH-only panel. Paloma shows it all, from a finger-prick test done at home, with results delivered digitally.

Then comes the care. Paloma's virtual endocrinologists are thyroid specialists — not generalists trying to fit thyroid disease into a packed schedule. Appointments are designed to give providers enough time to actually review results, understand the patient's symptom history, and make nuanced medication decisions. The question isn't just "is your TSH in range?" — it's "how do you feel, and what does the full picture of your labs say about why?"

And because thyroid care is inherently longitudinal — dosages drift, Hashimoto's progresses, life circumstances change metabolism — Paloma's symptom tracking system creates a continuous care loop. Patients log fatigue levels, weight changes, mood, temperature sensitivity, and other thyroid-specific symptoms between visits. When it's time for a retest, providers aren't starting from scratch. They're seeing a timeline. They're catching drift before it becomes a crisis.

Who Paloma Is For

Paloma's patient is not hard to find. She's the person who has been on levothyroxine for three years and still doesn't feel right. She's the person who went back to her doctor and was told her TSH is fine, so the problem must be something else — stress, maybe, or depression. She's the person who started researching T3 conversion issues at midnight because no one in the office would engage with her questions. She knows something is wrong. She just hasn't been able to get anyone to look closely enough.

More specifically, Paloma serves:

• Patients with Hashimoto's thyroiditis — the most common autoimmune disease in the US, often mismanaged because the autoimmune dimension is ignored after initial diagnosis
• Hypothyroid patients undertreated on levothyroxine alone — who may benefit from T3/T4 combination therapy but have never had a provider willing to explore it
• Newly diagnosed thyroid patients — who want to understand their condition from the start, not after years of frustrating appointments
• People with thyroid symptoms but no diagnosis — who have been dismissed because their TSH was "borderline" or "subclinical"
• Patients post-thyroidectomy — navigating hormone replacement after total or partial thyroid removal, a particularly complex optimization challenge

The common thread is patients who have been failed by a system designed around speed and simplicity, not complexity and chronicity. Paloma is for people who refuse to accept that feeling bad is their new normal.

Why Paloma Stands Out in a Crowded Telehealth Market

The telehealth space has exploded since 2020, but most platforms are generalist urgent care replacements — useful for strep throat, not for optimizing a patient's Free T3/Reverse T3 ratio. Paloma is different because it's deeply, almost obsessively, condition-specific.

Specialization creates compounding advantages. A thyroid-specific platform accumulates data that a generalist platform never will — symptom patterns correlated with specific lab ranges, medication adjustment outcomes, longitudinal autoimmune progression data. Over time, that data makes the clinical protocols smarter. The feedback loop between patient experience and provider decision-making tightens in ways that simply aren't possible when thyroid disease is one item on a long list of conditions a platform manages.

Paloma also bets on something that the current system systematically underweights: patient-reported outcomes matter. If a patient's TSH is 2.1 and they feel terrible, that is clinically relevant information. Paloma's platform treats it that way.

The Market: Massive, Underserved, and Chronic

Thyroid disease is not a niche condition. It's one of the most prevalent chronic illnesses in the developed world, with a strong female skew — women are 5 to 8 times more likely than men to develop thyroid conditions. The global thyroid therapeutics market is valued at over $3 billion and growing, but that figure undersells the opportunity because it counts only pharmaceuticals. The actual addressable market — testing, monitoring, specialist care, digital health tools — is far larger.

What makes this market particularly compelling for a platform like Paloma is the chronicity of the condition. Unlike acute care — which generates a single transaction — thyroid disease requires lifelong management. Every patient who joins Paloma isn't a one-time visitor; they're a longitudinal member who needs quarterly retesting, periodic medication adjustments, and ongoing access to specialist care. The unit economics of chronic care platforms, when done right, are fundamentally different from acute telehealth.

The timing is right for another reason: at-home diagnostics have matured. Consumer comfort with finger-prick blood tests — accelerated dramatically by the pandemic — means that the friction of getting a comprehensive thyroid panel done no longer requires a lab visit. The infrastructure Paloma needed to exist at scale is now available.

"No one should have to fight their doctor for a complete thyroid panel. No one should be told they're fine when they clearly aren't."

Built for Speed: How Paloma Came to Life on Artha

Paloma was built using Artha, an AI-native platform that takes a company from concept to launched product in a fraction of the time traditional development requires. The ability to move fast matters enormously in healthcare, where the window to establish category leadership is narrow and patient trust is the ultimate moat. Artha's AI-first approach allowed Paloma to stand up its brand, product architecture, and patient-facing experience without the months of back-and-forth that typically slow healthcare startups to a crawl.

The result is a platform that feels considered and clinical at the same time — designed to earn the trust of a patient population that has often been burned by dismissiveness, while moving with the agility of a technology company rather than a traditional health system.

What's Next for Paloma

The immediate opportunity is straightforward: reach the millions of thyroid patients who are currently symptomatic and underserved, give them the testing they should have had years ago, and connect them with providers who will actually engage with the complexity of their condition.

But the longer arc is more interesting. As Paloma builds its patient base, it accumulates something increasingly rare and valuable: longitudinal thyroid health data at scale. The correlation between symptom patterns, lab ranges, medication regimens, and outcomes — tracked continuously, not just at quarterly appointments — creates the foundation for a clinical intelligence layer that could meaningfully advance how thyroid disease is understood and treated.

There's also a broader condition adjacency play. Thyroid disease frequently co-occurs with other autoimmune and metabolic conditions — adrenal dysfunction, insulin resistance, Celiac disease, rheumatoid arthritis. A platform that earns deep patient trust around thyroid care is well-positioned to expand into the constellation of conditions that often travel with it.

The vision is a care model that is as persistent as the condition it treats — continuously present, continuously learning, and always oriented around whether the patient actually feels well, not whether their TSH falls within an arbitrary reference range.

Build Your Own Company on Artha

Paloma is one example of what becomes possible when you start with a clear problem, a patient population that desperately needs a better solution, and a platform that can turn that insight into a real company fast. The healthcare system is full of conditions that are mismanaged, patient populations that are underserved, and clinical protocols that haven't been updated since the 1990s. The opportunity to rebuild them — from the ground up, with modern tools and genuine ambition — has never been more accessible.

If you have a company idea — in healthcare, in any industry — Artha can help you build it. One prompt. A real company. Built by AI, launched for the world.

Visit artha.run to get started.